Meet Polyplus at booth #4 during the AIS in Montpellier, France from 20th - 21st June 2024. Don't miss to check out our Poster Presentation on the synergistic portfolio to be part of the Polyplus-Sartorius antibody solution.

Our team

Poster :

Polyplus-Sartorius: A Synergistic Portfolio to be Part of the Antibody Solution

Recently acquired by Sartorius, Polyplus is now part of the solution in the recombinant antibody production field. From  transfection reagents to plasmid design and antibody fragments production, we support customers in improving yield for protein production. In addition, Sartorius has a valuable  expertise in cell line development for antibody production, antibody screening and functional characterization.


Download Poster

Discover Our Applications

Cell & Gene Therapy

Success of Gene and Cell Therapies is dependent on efficient production of viral vectors that require optimized transfection reagents and viral vector engineering

RNA/DNA Therapeutics

RNA/DNA in vivo delivery is the most powerful alternative to viral vectors for nucleic acid-based therapies. They offer substantial advantages in terms of reliability,safety and costs for nucleic-acid based therapies

Protein Production

Broad range of solutions is needed for manufacturing of functional  proteins or antibodies at the desired scale in bacteria, yeast and mammalian cell expression systems

Life Sciences

Optimised plasmid engineering and specific transfection reagents are key to enable protein expression in a wide range of adherent and suspension mammalian cell types